Drugs / G1T38
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02821624 | May → Dec 2016 | — | G1 Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03455829 | Mar 2018 → Dec 2021 | non-small cell lung carcinoma | G1 Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02983071 | Jan 2017 → Jun 2023 | breast carcinoma | G1 Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G1T38 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02983071 ↗ |
| Action | Inhibit | “CDK 4/6 Inhibitor” NCT02821624 ↗ |
| Route | Oral | “G1T38 as an oral therapy” NCT02983071 ↗ |